Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SKYE

Skye Bioscience Inc

Mar 21 • 04:00PM ET

2.25

Dollar change +0.36
Percentage change 19.05	%

Healthcare • Biotechnology • USA • NASD

Peers: NBIX PCRX ACAD BMRN MDGL PRGO XENE CRIS VNDA TBPH

| Held by: VTI IWM VXF IWN VTWO IWC IWO VTWV RSSL VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.84	Insider Own	42.09%	Shs Outstand	30.34M	Perf Week	-10.00%
Market Cap	68.26M	Forward P/E	-	EPS next Y	-1.37	Insider Trans	-1.79%	Shs Float	17.57M	Perf Month	-28.12%
Income	-21.24M	PEG	-	EPS next Q	-0.29	Inst Own	43.95%	Short Float	12.33%	Perf Quarter	-30.77%
Sales	0.00M	P/S	-	EPS this Y	-60.50%	Inst Trans	-5.57%	Short Ratio	12.39	Perf Half Y	-57.06%
Book/sh	2.50	P/B	0.90	EPS next Y	-16.93%	ROA	-43.73%	Short Interest	2.17M	Perf Year	-83.33%
Cash/sh	2.52	P/C	0.89	EPS next 5Y	-	ROE	-54.82%	52W Range	1.83 - 17.65	Perf YTD	-20.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.94%	ROI	-27.98%	52W High	-87.25%	Beta	1.82
Dividend TTM	-	Quick Ratio	14.19	Sales past 5Y	0.00%	Gross Margin	-	52W Low	23.29%	ATR (14)	0.30
Dividend Ex-Date	-	Current Ratio	14.19	EPS Y/Y TTM	90.92%	Oper. Margin	-	RSI (14)	41.91	Volatility	13.27% 10.32%
Employees	11	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	16.60
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	96.83%	Payout	-	Rel Volume	3.82	Prev Close	1.89
Sales Surprise	-	EPS Surprise	13.79%	Sales Q/Q	-	Earnings	Mar 20 AMC	Avg Volume	174.89K	Price	2.25
SMA20	-11.57%	SMA50	-19.33%	SMA200	-52.68%	Trades		Volume	667,757	Change	19.05%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Initiated	William Blair	Outperform
Sep-30-24	Initiated	Scotiabank	Sector Outperform	$20
Sep-10-24	Initiated	JMP Securities	Mkt Outperform	$15
Jul-09-24	Initiated	Craig Hallum	Buy	$18
May-23-24	Initiated	Cantor Fitzgerald	Overweight	$21
Apr-12-24	Initiated	Oppenheimer	Outperform	$25

Mar-20-25 09:59PM	Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period (SeekingAlpha) -5.50% +19.05%
09:58PM	Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:01PM	Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
10:00AM	Here are the major earnings after the close today (SeekingAlpha)
Mar-19-25 05:35PM	Skye Bioscience Q4 2024 Earnings Preview (SeekingAlpha) -12.66%
07:00AM	Loading…
Mar-14-25 07:00AM	Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025 (GlobeNewswire)
Feb-27-25 06:00PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.34%
Feb-24-25 07:00AM	Skye Bioscience to Participate in SXSW Session on Obesity (GlobeNewswire)
Feb-20-25 07:00AM	Skye Bioscience to Present at TD Cowen Health Care Conference (GlobeNewswire)
Feb-04-25 07:00AM	Skye Bioscience Announces Participation in February Conferences (GlobeNewswire)
Jan-13-25 07:00AM	Skye Bioscience Provides 2025 Look Ahead and Year in Review (GlobeNewswire)
Dec-19-24 07:00AM	Skye Bioscience to Present at J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-18-24 07:00AM	Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences (GlobeNewswire) -7.88%
Nov-15-24 07:45AM	Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond (TipRanks) -10.16%
Nov-14-24 07:00AM	Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor (GlobeNewswire)
04:01PM	Loading…
Nov-07-24 04:01PM	Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Nov-04-24 07:00AM	Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model (GlobeNewswire)
Nov-01-24 07:00AM	Skye Bioscience to Announce Third Quarter 2024 Results (GlobeNewswire) +6.11%
Oct-29-24 07:00AM	Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board (GlobeNewswire)
Oct-21-24 07:00AM	Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences (GlobeNewswire)
Sep-23-24 07:00AM	Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan (GlobeNewswire) +11.15%
Sep-03-24 07:00AM	Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer (GlobeNewswire)
Aug-26-24 07:00AM	Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences (GlobeNewswire) +15.29%
Aug-23-24 06:45PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.69%
Aug-22-24 07:00AM	Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity (GlobeNewswire)
Aug-09-24 05:59PM	Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) -9.42%
Jul-24-24 07:30AM	Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND Phase 2 Trial of Nimacimab for Obesity (GlobeNewswire)
06:00AM	Skye Bioscience Hosts Virtual KOL Event, "Metabolic Rewiring with CB1 Inhibition," and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints (GlobeNewswire)
Jul-11-24 07:15AM	Skye Bioscience to Host Virtual KOL Event, Metabolic Rewiring with CB1 Inhibition, on July 24th (GlobeNewswire) +6.90%
07:00AM	Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab (GlobeNewswire)
07:00AM	Loading…
Jul-03-24 07:00AM	Skye Bioscience Appoints Dr. Karen Smith to Board of Directors (GlobeNewswire)
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
07:00AM	Skye Bioscience Added to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-25-24 07:00AM	Skye BioScience Participating in Piper Sandler Virtual Obesity Day (GlobeNewswire) -6.19%
Jun-10-24 08:22AM	Skye Bioscience ends eye disease R&D efforts after glaucoma drug's phase 2 fail (FierceBiotech.com) -8.78%
07:00AM	Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program (GlobeNewswire)
Jun-03-24 07:00AM	Skye Bioscience to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-10-24 07:00AM	Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting (GlobeNewswire) -6.21%
May-07-24 11:59AM	Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program (News Direct)
Apr-30-24 07:00AM	Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting (GlobeNewswire)
Apr-23-24 07:00AM	Skye Bioscience to Present at Upcoming Investment Conferences (GlobeNewswire) -5.27%
Apr-10-24 08:00AM	Skye Bioscience Uplists to The Nasdaq Global Market (GlobeNewswire) +39.69%
Mar-11-24 09:20AM	Skye Bioscience Announces $40 Million Private Placement Equity Financing (Newsfile) -24.95%
Mar-04-24 07:00AM	Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors (GlobeNewswire) +7.59%
Feb-26-24 07:00AM	Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension (GlobeNewswire) +13.82%
Feb-07-24 07:00AM	Skye Bioscience to Present at Oppenheimer Investor Conference (Newsfile) -7.55%
Jan-29-24 08:00AM	Skye Bioscience Announces $50.25 Million Private Placement Equity Financing (Newsfile) +29.03%

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Diep Tuan Tu	Chief Development Officer	Nov 18 '24	Sale	4.99	19,489	97,250	82,259	Nov 20 08:23 AM
Diep Tuan Tu	Chief Development Officer	Nov 15 '24	Sale	5.55	85	472	101,748	Nov 20 08:23 AM
ARSENAULT KAITLYN	Chief Financial Officer	Nov 18 '24	Sale	4.99	43,206	215,598	166,342	Nov 19 09:57 PM
ARSENAULT KAITLYN	Chief Financial Officer	Nov 15 '24	Sale	5.55	190	1,054	209,548	Nov 19 09:57 PM
DHILLON PUNIT	Chief Executive Officer	Nov 18 '24	Sale	4.99	82,546	411,905	329,823	Nov 19 09:20 PM
DHILLON PUNIT	Chief Executive Officer	Nov 15 '24	Sale	5.55	364	2,020	412,369	Nov 19 09:20 PM
Grayson Paul A.	Director	Nov 18 '24	Sale	4.99	86,244	430,358	259,701	Nov 19 09:14 PM
Grayson Paul A.	Director	Nov 15 '24	Sale	5.55	307	1,704	345,945	Nov 19 09:14 PM
ARSENAULT KAITLYN	Officer	Nov 15 '24	Proposed Sale	5.51	57,084	314,533		Nov 15 05:31 PM
DHILLON PUNIT	Officer	Nov 15 '24	Proposed Sale	5.51	100,693	554,818		Nov 15 05:28 PM
Diep Tuan Tu	Officer	Nov 15 '24	Proposed Sale	5.51	22,877	126,052		Nov 15 05:25 PM
Grayson Paul A.	Director	Nov 15 '24	Proposed Sale	5.51	86,804	478,290		Nov 15 05:22 PM
Schwab Andrew J.	Director	Sep 11 '24	Sale	6.60	252,500	1,666,500	66,356	Sep 13 06:56 PM
Schwab Andrew J.	Director	Sep 13 '24	Sale	6.06	13,837	83,852	66,277	Sep 13 06:56 PM
5AM Partners VII, LLC	10% Owner	Sep 11 '24	Sale	6.60	252,500	1,666,500	66,356	Sep 13 06:54 PM
5AM Partners VII, LLC	10% Owner	Sep 13 '24	Sale	6.06	13,837	83,852	66,277	Sep 13 06:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SKYE

Skye Bioscience Inc

Upgrade your FINVIZ experience